Table 3.

Pharmacokinetic parameters of secukinumab following a single 300 mg subcutaneous injection in healthy male and female subjects

	AUClast	AUCinf	Cmax	tmax a	Vz/F	CL/F	t1/2
	(μg.day)/mL	(μg.day)/mL	μg/mL	day	L	L/day	day
AI (2 × 1 mL)
N	19	19	20	20	19	19	19
Mean	1610	1810	35.2	‐	9.71	0.223	32.1
SD	606	720	11.4	‐	7.31	0.202	6.36
CV%	37.7	39.9	32.3	‐	75.2	90.2	19.8
Median	1710	1950	39.7	4.48	7.80	0.154	30.4
Range	282–2490	298–3080	7.66–48.7	2.94–10.1	4.58–37.6	0.0975–1.01	22.5–43.3
Twin‐01 (2 × 1 mL)
N	19	19	20	20	19	19	19
Mean	1730	1940	38.0	‐	7.38	0.166	31.9
SD	456	535	9.79	‐	1.74	0.047	7.57
CV%	26.4	27.5	25.7	‐	23.6	28.5	23.7
Median	1710	2010	37.5	7.00	7.25	0.149	30.0
Range	1090–2580	1130–3040	25.3–53.4	2.05–34.9	4.60–10.3	0.0988–0.265	20.9–48.7
Pump (90 s)
N	18	18	20	20	18	18	18
Mean	1520	1700	34.1	‐	8.64	0.184	33.0
SD	304	364	6.88	‐	1.60	0.038	4.97
CV%	19.9	21.4	20.2	‐	18.6	20.7	15.1
Median	1500	1650	32.9	4.97	8.53	0.182	31.0
Range	1100–2090	1200–2420	24.7–46.0	2.00–14.0	5.85–11.4	0.124–0.249	26.8–42.4
Smartdose
N	19	19	20	20	19	19	19
Mean	1690	1840	40.4	‐	6.89	0.174	28.4
SD	400	475	9.45	‐	1.34	0.045	5.69
CV%	23.7	25.9	23.4	‐	19.4	25.9	20.0
Median	1630	1700	39.4	4.50	6.60	0.177	27.4
Range	1050–2510	1070–2810	22.6–56.7	3.00–9.99	5.34–9.70	0.107–0.279	17.7–39.8
Manual (10 s)
N	20	20	20	20	20	20	20
Mean	1860	2050	42.1	‐	6.49	0.154	30.2
SD	371	488	6.95	‐	1.24	0.037	7.22
CV%	20.0	23.8	16.5	‐	19.1	24.1	23.9
Median	1850	1970	43.0	6.00	6.50	0.153	27.6
Range	1180–2580	1200–3280	29.1–53.5	2.03–10.0	4.04–8.35	0.0931–0.249	21.1–48.7
PFS (2 × 1 mL)
N	19	19	21	21	19	19	19
Mean	1620	1760	40.8	‐	7.65	0.189	28.4
SD	463	549	12.6	‐	3.28	0.068	5.26
CV%	28.6	31.2	31.0	‐	42.9	36.3	18.5
Median	1660	1770	45.1	4.90	6.36	0.170	26.7
Range	669–2720	749–3220	12.6–61.8	1.95–14.1	5.46–19.0	0.0931–0.400	20.1–40.7

^amedian and range only are given for t_max.